Imagine a world where the fight against tuberculosis (TB) is significantly bolstered by cutting-edge technology. Researchers at the University of Melbourne’s Microbiological Diagnostic Unit Public Health Laboratory, part of the Doherty Institute, have introduced a groundbreaking genomic software tool that offers an open-access solution for clinicians. This innovative tool allows for precise identification of antibiotic resistance in TB, enabling healthcare providers to tailor their treatment approaches effectively.
The software, known as tbtAMR, plays a crucial role in expediting diagnosis and facilitating more targeted therapeutic interventions. This means improved health outcomes for patients and enhanced responsible use of antibiotics in the ongoing battle against drug-resistant TB.
Notably, tbtAMR is the world’s first ISO-accredited tool of its kind. It meticulously analyzes the genetic material of Mycobacterium tuberculosis—the bacterium responsible for TB—to uncover mutations associated with drug resistance. The results are presented in a format that is ready for clinical application, allowing physicians to receive timely information about the most effective treatments based on each patient’s specific situation.
Despite being one of the leading causes of infectious disease mortality globally, the challenge posed by increasing rates of drug-resistant TB underscores the urgent need for accurate and prompt treatment decisions. While advancements in whole-genome sequencing have revolutionized TB research, applying these technologies in clinical settings has been hampered due to the absence of validated testing methodologies that laboratories could confidently utilize for patient care. However, the tbtAMR tool is changing this landscape, as detailed in a recent publication in The Lancet Digital Health.
Dr. Kristy Horan from the University of Melbourne, who serves as a bioinformatician at the Doherty Institute and is the primary author of the study, emphasizes that tbtAMR is not only effective but also specifically designed to be user-friendly in real-world clinical environments, even those lacking specialized bioinformatics knowledge.
“In our research, tbtAMR accurately identified resistance to first-line TB medications in nearly 95% of instances while detecting drug-susceptible infections with over 97% accuracy,” Dr. Horan explained. “Its performance either matched or surpassed that of other commonly used genomic tools.”
This transformative tool is already integrated into routine clinical use at the Doherty Institute, delivering results that align with the timelines of traditional laboratory testing. It can process standard sequencing files and detects a broad spectrum of genetic alterations tied to antibiotic resistance, quickly providing insights into which drugs are likely to be effective for individual patients. This feature makes tbtAMR an invaluable resource for managing drug-resistant TB, particularly in settings with limited resources.
Extensive testing, utilizing more than 15,000 TB genome sequences from various public databases and accredited labs, has demonstrated that tbtAMR consistently identifies resistance mutations and traces TB lineages across a wide array of samples, confirming its reliability in practical applications.
Associate Professor Norelle Sherry, Deputy Director at MDU PHL at the Doherty Institute and senior author of the paper, highlighted that the team has established rigorous protocols to ensure that laboratories can utilize tbtAMR with precision, instilling confidence among doctors and patients regarding the results.
“Our aim was not only to create a robust tool but also to ensure it could be trusted in actual clinical environments and made easily accessible,” stated Associate Professor Sherry.
In an effort to promote the widespread adoption of this innovative tool, the MDU PHL team has made tbtAMR freely available on the Centre for Pathogen Genomics portal. Designed to operate on a user-friendly Windows interface, the tool does not necessitate command-line skills, thereby democratizing access to high-quality genomic testing on a global scale.
Furthermore, the validation datasets, reporting templates, and accreditation guidelines for tbtAMR have also been released for other laboratories, enabling them to implement and gain accreditation for this tool within their respective facilities.
“By ensuring free and public access to tbtAMR, we empower laboratories around the world—especially in low- and middle-income regions—to efficiently analyze TB genomic data, generating outputs that clinicians can use to optimize patient management,” Associate Professor Sherry added.
